Clinical Effect of Rebamipide on Chronic Gastritis
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 180
- 主要终点
- modified Lanza score
研究概览
简要总结
To investigate the clinical effect of rebamipide in chronic gastritis patients. Patients with chronic gastritis were randomly divided into the experimental group and the control group. The experimental group were treated with rebamipide 0.1g tid and optimization of life style, and the control group were only optimized their life style for 26 weeks. Upper gastrointestinal endoscopy was performed in all patients to evaluate the severity of gastritis by modified Lanza score (MLS) and the histology by the updated Sydney system before and after treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •With the symptoms as follow: epigastric pain, abdominal discomfort, abdominal distention, poor appetite, nausea, vomiting and so on
- •diagnosed as chronic gastritis with endoscopic and pathological methods
- •agree to join in this clinical trail
排除标准
- 未提供
研究组 & 干预措施
experimental
The experimental group were treated with rebamipide 0.1g tid and optimization of life style.
干预措施: Rebamipide (Drug)
experimental
The experimental group were treated with rebamipide 0.1g tid and optimization of life style.
干预措施: optimization of life style (Behavioral)
control
The control group were only optimized their life style.
干预措施: optimization of life style (Behavioral)
结局指标
主要结局
modified Lanza score
时间窗: 26 weeks
visual Analog scale
时间窗: 26 weeks
to describe the inflamamtory of gastric mucosa pathologically
次要结局
未报告次要终点
研究者
BangMao Wang
Chief of Gastroenterology Department
Tianjin Medical University General Hospital